Richard Nowak, MD, MS

Richard Nowak, MD, MS, discusses remaining questions surrounding inebilizumab in generalized myasthenia gravis, including long-term durability, biomarker development, and the need for real-world and expanded population data.

Richard Nowak, MD, MS, discusses how inebilizumab fits within the current gMG treatment landscape, highlighting its upstream CD19-targeted mechanism and sustained clinical benefit compared with other biologic strategies.

Richard Nowak, MD, MS, discusses pharmacodynamic findings from the MINT trial, highlighting rapid and sustained B-cell depletion with inebilizumab and the current limitations of biomarkers in predicting clinical response.

Richard Nowak, MD, MS, reviews 52-week efficacy data from the MINT trial, highlighting durable improvements in MG-ADL and QMG scores and what the evolving treatment-placebo separation means for long-term disease control.

Richard Nowak, MD, MS, outlines the design of the phase 3 MINT trial, highlighting its patient population, forced steroid taper, and the rationale for extending evaluation to a 52-week randomized control period.

Richard Nowak, MD, MS, outlines the biologic rationale for CD19-targeted therapy in generalized myasthenia gravis, highlighting how inebilizumab differs from CD20-directed approaches and why broader B-cell depletion may offer clinical advantages.

The associate professor of neurology at Yale School of Medicine discussed 52-week data from the phase 3 MINT trial of inebilizumab in patients with generalized myasthenia gravis. [WATCH TIME: 5 minutes]

The director of the myasthenia gravis clinic at Yale University provided additional insight on the MINT study of inebilizumab in myasthenia gravis, some of the subanalyses within, and next plans in the drug’s development. [WATCH TIME: 5 minutes]

The director of the myasthenia gravis clinic at Yale University provided clinical insight on promising phase 3 data assessing inebilizumab, an FDA-approved therapy for NMOSD, in patients with myasthenia gravis. [WATCH TIME: 4 minutes]

The assistant professor of neurology at the Yale School of Medicine spoke about the strength in the patient-clinician relationship in ensuring quality care for myasthenia gravis. [WATCH TIME: 4 minutes]

The assistant professor of neurology at Yale School of Medicine spoke about the importance of the relaunch of the patient registry for research in myasthenia gravis. [WATCH TIME: 3 minutes]